HIF-1 as a target for drug development
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, growing evidence showed that the strong cell–cell contacts of tumor spheroids in combination with dense ECM deposition is responsible for chemoresistance by posing a physical barrier to the penetration of chemotherapeutics and immune cells similar to in vivo.[ 48 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [48]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Most importantly, overexpression of HIF-1α or HIF-2α have been implicated as poor prognostic indicators for a variety of tumour”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Purification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
HIF-1α is essential for myeloid cell-mediated inflammation
Cramer, T., Yamanishi, Y., Clausen, B. E., Förster, I., Pawlinski, R., Mackman, N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00154-5 · Cited by 2,046
Self-citationCantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006 · cited 1×
“The PTEN tumour-suppressor gene is mutated or inactivated in a large percentage of glioblastoma”
BackgroundTranscriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
Semenza, G. L., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,897 · cited 1×
“jpg" NDATA ITEM> ]> Adaptation of cells to an anaerobic environment is achieved by the transcriptional induction of genes that are involved in glycolysi”
BackgroundThe unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
Self-citationGuba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739 · cited 1×
“An analogue of rapamycin, CCI779, is presently in clinical trials, and has been suggested to work as an antitumour agent by inhibiting expression of pro-angiogenic factors such as VEG”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579 · cited 1×
“were the first to demonstrate that loss of HIF-1 severely impedes tumour growth and the induction of pro-angiogenic gene expressio”
BackgroundSelf-citationOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558
Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550
(2000) · PubMed · Cited by 1,445
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Tian, H., McKnight, S. L., & Russell, D. W. (1997) · Genes & Development · doi:10.1101/gad.11.1.72 · Cited by 1,351 · cited 1×
“cgi?l=2034">HIF-2α (also known as endothelial PAS domain protein 1 (EPAS1), or MOP2”
BackgroundLaughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 1×
“This overexpression of HIF-1α is due to both hypoxia-dependent as well as hypoxia-independent pathways, such as oncogene activation and glucose deprivatio”
BackgroundSCF and Cullin/RING H2-Based Ubiquitin Ligases
Deshaies, R. J. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.435 · Cited by 1,242 · cited 1×
“These are directly involved in the ubiquitylation of proteins targeted for degradation by the 26S proteasom”
BackgroundHuang, L. E., Arany, Z., Livingston, D. M., & Bunn, H. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.32253 · Cited by 1,190
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186 · cited 1×
“A recent study indicates that inhibition of TOR using rapamycin results in decreased HIF-1α stabilization and transactivatio”
BackgroundSelf-citationDimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
Jiang, B.-H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17771 · Cited by 1,106 · cited 1×
“Both HIF-1α and HIF-1β are members of the basic helix–loop–helix PER/ARNT/SIM ( HLH–PAS ) family of transcription factor”
BackgroundCockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,050
Regulation of the Erythropoietin Gene: Evidence That the Oxygen Sensor Is a Heme Protein
Goldberg, M. A., Dunning, S. P., & Bunn, H. F. (1988) · Science · doi:10.1126/science.2849206 · Cited by 1,031
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization
Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., & Gu, W. (2002) · Nature · doi:10.1038/nature737 · Cited by 1,031 · cited 1×
“The precedence for such a paradigm has recently been reported for the p53 tumour-suppressor gene through the identification of HAUSP, a herpes virus ubiquitin-specific proteas”
BackgroundEma, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016 · cited 1×
“cgi?l=2034">HIF-2α (also known as endothelial PAS domain protein 1 (EPAS1), or MOP2”
BackgroundEnhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969 · cited 1×
“Interestingly, cells that possess PTEN mutations are far more sensitive to rapamycin than cells that possess functional PTE”
BackgroundTanimoto, K., Makino, Y., Pereira, T., & Poellinger, L. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4298 · Cited by 928
Signal transduction to hypoxia-inducible factor 1
Semenza, G. L. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01168-1 · Cited by 860 · cited 1×
“This overexpression of HIF-1α is due to both hypoxia-dependent as well as hypoxia-independent pathways, such as oncogene activation and glucose deprivatio”
BackgroundLoss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840 · cited 1×
“HIF-1 transcription activity and the expression of angiogenic factors are subjected to regulation by the PI3K/AKT pathwa”
BackgroundSelf-citationLu, H., Forbes, R. A., & Verma, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202487200 · Cited by 837 · cited 1×
“This overexpression of HIF-1α is due to both hypoxia-dependent as well as hypoxia-independent pathways, such as oncogene activation and glucose deprivatio”
BackgroundStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827
Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2.
Feldser, D. M., Agani, F. H., Iyer, N. V., Pak, B. J., Ferreira, G., & Semenza, G. L. (1999) · PubMed · Cited by 782
Maltepe, E., Schmidt, J. V., Baunoch, D., Bradfield, C. A., & Simon, M. C. (1997) · Nature · doi:10.1038/386403a0 · Cited by 781 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundRbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
Kamura, T., Koepp, D. M., Conrad, M. N., Skowyra, D., Moreland, R. J., Iliopoulos, O., Lane, W. S., Kaelin, W. G., Elledge, S. J., Conaway, R. C., et al. (1999) · Science · doi:10.1126/science.284.5414.657 · Cited by 781
Gu, Y.-Z., Moran, S. M., Hogenesch, J. B., Wartman, L. D., & Bradfield, C. A. (1998) · Europe PMC (PubMed Central) · Cited by 769
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730 · cited 1×
“demonstrated that 2-ME2 inhibits HIF-1α at the post-transcriptional level, prevents HIF-1 target gene expression in tumour cells and inhibits HIF-2α in human endothelial cell”
BackgroundHewitson, K. S., McNeill, L. A., Riordan, M. V., Tian, Y.-M., Bullock, A. N., Welford, R. W., Elkins, J. M., Oldham, N. J., Bhattacharya, S., Gleadle, J. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200273200 · Cited by 719
Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation
Jeong, J.-W., Bae, M.-K., Ahn, M.-Y., Kim, S.-H., Sohn, T.-K., Bae, M.-H., Yoo, M.-A., Song, E. J., Lee, K.-J., & Kim, K.-W. (2002) · Cell · doi:10.1016/s0092-8674(02)01085-1 · Cited by 716
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705 · cited 1×
“Another mechanism of regulating HIF-1 is the inhibition of HIF-1α and HIF-1β dimerization, which is achieved through competitive binding of an inhibitory PAS (IPAS) molecul”
BackgroundHsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 653 · cited 1×
“By contrast, the β-domain of VHL directly interacts with HIF-1&alpha”
BackgroundTransactivation and Inhibitory Domains of Hypoxia-inducible Factor 1α
Jiang, B.-H., Zheng, J. Z., Leung, S. W., Roe, R., & Semenza, G. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19253 · Cited by 629 · cited 1×
“One domain is localized between residues 531–575, and is important in modulating HIF-1α protein stability, and is therefore referred to as the OXYGEN-DEPENDENT DEGRADATION (ODD) domai”
BackgroundEma, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1905 · Cited by 587
Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha /ARNT
Zelzer, E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5085 · Cited by 575
Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein
Duan, D. R., Pause, A., Burgess, W. H., Aso, T., Chen, D. Y. T., Garrett, K. P., Conaway, R. C., Conaway, J. W., Linehan, W. M., & Klausner, R. D. (1995) · Science · doi:10.1126/science.7660122 · Cited by 568 · cited 1×
“The α-domain of VHL binds to elongin C through amino acids 157–171, and their interaction is stabilized in the presence of TCEB”
Background(2001) · PubMed · Cited by 557
Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G. L., & Van Obberghen, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204152200 · Cited by 539
Jiang, B., Agani, F. H., Passaniti, A., & Semenza, G. L. (1997) · PubMed · Cited by 532
Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α Subunit
Pugh, C. W., O'Rourke, J. F., Nagao, M., Gleadle, J. M., & Ratcliffe, P. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.17.11205 · Cited by 532
Hogenesch, J. B., Chan, W. K., Jackiw, V. H., Brown, R. C., Gu, Y.-Z., Pray-Grant, M., Perdew, G. H., & Bradfield, C. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8581 · Cited by 513
Mazure, N. M., Chen, E. Y., Laderoute, K. R., & Giaccia, A. J. (1997) · Blood · doi:10.1182/blood.v90.9.3322 · Cited by 503
Self-citationSuppression of tumor growth through disruption of hypoxia-inducible transcription
Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., & Livingston, D. M. (2000) · Nature Medicine · doi:10.1038/82146 · Cited by 501
Pause, A., Lee, S., Worrell, R. A., Chen, D. Y. T., Burgess, W. H., Linehan, W. M., & Klausner, R. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2156 · Cited by 493
YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1
Yeo, E.-J., Chun, Y.-S., Cho, Y.-S., Kim, J., Lee, J.-C., Kim, M.-S., & Park, J.-W. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.7.516 · Cited by 476 · cited 1×
“indicate that YC-1 inhibits HIF-1α protein stability and transactivation of downstream effector genes in cell culture studie”
BackgroundOncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.861 · Cited by 469 · cited 1×
“HIF-1 transcription activity and the expression of angiogenic factors are subjected to regulation by the PI3K/AKT pathwa”
BackgroundTOR signalling and control of cell growth
Thomas, G., & Hall, M. N. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80078-6 · Cited by 462 · cited 1×
“cgi?l=6097">TOR ) (also known as RAR-related orphan receptor C (RORC)”
Background(2002) · PubMed · Cited by 457
How the Cyclin Became a Cyclin
Koepp, D. M., Harper, J. W., & Elledge, S. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80753-9 · Cited by 445
Relation of vascular proliferation to tumor growth.
Folkman, J., & Cotran, R. S. (1976) · PubMed · Cited by 411
YC-1, a novel activator of platelet guanylate cyclase
Ko, F., Wu, C., Kuo, S., Lee, F., & Teng, C. (1994) · Blood · doi:10.1182/blood.v84.12.4226.bloodjournal84124226 · Cited by 402
Carrero, P., Okamoto, K., Coumailleau, P., O'Brien, S., Tanaka, H., & Poellinger, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.402-415.2000 · Cited by 385 · cited 1×
“HIF-1α is regulated by redox factor 1 (REF-1) and thioredoxi”
BackgroundLonergan, K. M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R. C., Conaway, J. W., & Kaelin, W. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.732 · Cited by 381
Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H., & Poellinger, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200328200 · Cited by 375 · cited 1×
“Another mechanism of regulating HIF-1 is the inhibition of HIF-1α and HIF-1β dimerization, which is achieved through competitive binding of an inhibitory PAS (IPAS) molecul”
BackgroundThe regulated expression of erythropoietin by two human hepatoma cell lines.
Goldberg, M. A., Glass, G. A., Cunningham, J. M., & Bunn, H. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.7972 · Cited by 357
Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Meir, E. G. V., Simons, J. W., & Zhong, H. (2002) · PubMed · Cited by 338
Vincent, K. A., Shyu, K.-G., Luo, Y., Magner, M., Tio, R. A., Jiang, C., Goldberg, M. A., Akita, G. Y., Gregory, R. J., & Isner, J. M. (2000) · Circulation · doi:10.1161/01.cir.102.18.2255 · Cited by 317
Proteolysis and the cell cycle: with this RING I do thee destroy
Tyers, M., & Jorgensen, P. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00049-0 · Cited by 310
p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription
Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel, J., Fojo, T., & Neckers, L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.11995 · Cited by 283
(2001) · PubMed · Cited by 270
Role of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α
Chan, D. A., Sutphin, P. D., Denko, N. C., & Giaccia, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206922200 · Cited by 264
Self-citation(2003) · PubMed · Cited by 250
Semenza, G. L., Koury, S. T., Nejfelt, M. K., Gearhart, J. D., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8725 · Cited by 249 · cited 1×
“In the early 1990s, several groups demonstrated that the hypoxic inducibility of the EPO gene is due in part to a HYPOXIA-RESPONSE ELEMENT (HRE), 5'-ACGTG-3', localized in its 3' flanking regio”
Background2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate
Pribluda, V. S., Gubish, E. R., Gubish, E. R., LaVallee, T. M., Treston, A., Swartz, G. M., & Green, S. J. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026543018478 · Cited by 240
Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R., & Giaccia, A. J. (1996) · PubMed · Cited by 239
Self-citationMAP Kinases and Hypoxia in the Control of VEGF Expression
Berra, E., Pagès, G., & Pouysségur, J. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026506011458 · Cited by 223
McNEILL, L. A., HEWITSON, K. S., CLARIDGE, T. D., SEIBEL, J. F., HORSFALL, L. E., & SCHOFIELD, C. J. (2002) · Biochemical Journal · doi:10.1042/bj20021162 · Cited by 215
Involvement of Hypoxia-Inducible Factor 1 in Human Cancer.
SEMENZA, G. L. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.79 · Cited by 208 · cited 1×
“However, tumour cells might have a greater requirement for HIF-1, and many seem to express HIF-1α both under hypoxic and oxic condition”
BackgroundGraham, C. H., Forsdike, J., Fitzgerald, C. J., & Macdonald-Goodfellow, S. K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990209)80:4<595::aid-ijc18>3.0.co;2-b · Cited by 195
Lando, D., Pongratz, I., Poellinger, L., & Whitelaw, M. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.7.4618 · Cited by 178 · cited 1×
“HIF-1α is regulated by redox factor 1 (REF-1) and thioredoxi”
BackgroundPark, S.-K., Dadak, A. M., Haase, V. H., Fontana, L., Giaccia, A. J., & Johnson, R. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.14.4959-4971.2003 · Cited by 169
Self-citationTelomerase in human development and cancer
Shay, J. W. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199711)173:2<266::aid-jcp33>3.0.co;2-b · Cited by 162
Hypoxia-inducible factor-1α is regulated at the post-mRNA level
Wenger, R. H., Kvietiko, I., Rolfs, A., Gassmann, M., & Marti, H. H. (1997) · Kidney International · doi:10.1038/ki.1997.79 · Cited by 162
Sodhi, A., Montaner, S., Miyazaki, H., & Gutkind, J. S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5532 · Cited by 161 · cited 1×
“Both the PI3K and MAP kinase pathways support a role for growth-factor-receptor signalling in HIF-1α stabilizatio”
BackgroundSun, X., Kanwar, J. R., Leung, E. Y., Lehnert, K., Wang, D., & Krissansen, G. W. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301388 · Cited by 158
Belanger, A. J., Lu, H., Date, T., Liu, L. X., Vincent, K. A., Akita, G. Y., Cheng, S. H., Gregory, R. J., & Jiang, C. (2002) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2002.2021 · Cited by 152 · cited 1×
“There have also been a number of interesting studies of induced expression of HIF-1α in cardiomyocytes; this is another cell type with great potential for drugs and treatments that can prevent damage caused by hypoxia and ischaemi”
BackgroundMolecular Mechanism of Hypoxia-inducible Factor 1α-p300 Interaction
Gu, J., Milligan, J., & Huang, E. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009522200 · Cited by 143 · cited 1×
“Under these conditions, C-TAD is able to interact with transcriptional co-activators such as P300/CB”
BackgroundSrinivas, V., Zhang, L.-P., Zhu, X.-H., & Caro, J. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0878 · Cited by 140 · cited 1×
“Interestingly, the ability to confer oxygen sensitivity to heterologous proteins is transferable from HIF-1α to other protein”
BackgroundNwogu, J. I., Geenen, D., Bean, M., Brenner, M. C., Huang, X., & Buttrick, P. M. (2001) · Circulation · doi:10.1161/hc4301.097193 · Cited by 131 · cited 1×
“There have also been a number of interesting studies of induced expression of HIF-1α in cardiomyocytes; this is another cell type with great potential for drugs and treatments that can prevent damage caused by hypoxia and ischaemi”
BackgroundÁlvarez-Tejado, M., Alfranca, A., Aragonés, J., Vara, A., Landázuri, M. O., & del Peso, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200017200 · Cited by 127
Activated pp60c-Src Leads to Elevated Hypoxia-inducible Factor (HIF)-1α Expression under Normoxia
Karni, R., Dor, Y., Keshet, E., Meyuhas, O., & Levitzki, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206141200 · Cited by 116
A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses
Chun, Y., Choi, E., Yeo, E.-J., Lee, J.-H., Kim, M.-S., & Park, J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.22.4051 · Cited by 109
The pVHL-HIF-1 system: A key mediator of oxygen homeostasis
Maxwell, P., Pugh, C. W., & Ratcliffe, P. J. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-3401-0_24 · Cited by 100
Tanguay, R. L., Andreasen, E. A., Heideman, W., & Peterson, R. E. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00225-6 · Cited by 100 · cited 1×
“Alternatively spliced variants of HIF-1α and HIF-1β have also been reported, indicating that these molecules could represent an additional mechanism of maintaining stringent HIF-1 regulatio”
BackgroundMicrotubule Disruption Utilizes an NFκB-dependent Pathway to Stabilize HIF-1α Protein
Jung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J., & Neckers, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209804200 · Cited by 99
Pause, A., Peterson, B. S., Schaffar, G., Stearman, R. S., & Klausner, R. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9533 · Cited by 96
A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1α gene
Chun, Y., Choi, E., Kim, T., Kim, M.-S., & Park, J. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3620071 · Cited by 74
Harnessing the Response to Tissue Hypoxia HIF-1α and Therapeutic Angiogenesis
Vincent, K. A., Féron, O., & Kelly, R. A. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00186-x · Cited by 70
The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
Moyal, E. C., Evans, S. M., Koch, C. J., Muschel, R. J., McKenna, W. G., Wu, J., & Bernhard, E. J. (2001) · PubMed · Cited by 70
Regulatory elements of the erythropoietin gene
Imagawa, S., Goldberg, M., Doweiko, J. P., & Bunn, H. F. (1991) · Blood · doi:10.1182/blood.v77.2.278.278 · Cited by 64 · cited 1×
“In the early 1990s, several groups demonstrated that the hypoxic inducibility of the EPO gene is due in part to a HYPOXIA-RESPONSE ELEMENT (HRE), 5'-ACGTG-3', localized in its 3' flanking regio”
BackgroundKurebayashi, J., Otsuki, T., Kurosumi, M., Soga, S., Akinaga, S., & Sonoo, H. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02159.x · Cited by 60 · cited 1×
“At present, geldanamycin has been derivatized to a less toxic form that could potentially be used in the clinic to inhibit HIF-1 (Ref”
BackgroundCell-specificity and signaling pathway of endothelin-1 gene regulation by hypoxia
Bódi, I., Bishopric, N. H., Discher, D. J., Wu, X., & Webster, K. A. (1995) · Cardiovascular Research · doi:10.1016/s0008-6363(95)00164-6 · Cited by 59
Jiang, C., Lu, H., Vincent, K. A., Shankara, S., Belanger, A. J., Cheng, S. H., Akita, G. Y., Kelly, R. A., Goldberg, M. A., & Gregory, R. J. (2002) · Physiological Genomics · doi:10.1152/physiolgenomics.00058.2001 · Cited by 58
Jung, F., Haendeler, J., Hoffmann, J., Reissner, A., Dernbach, E., Zeiher, A. M., & Dimmeler, S. (2002) · Circulation Research · doi:10.1161/01.res.0000024412.24491.ca · Cited by 53 · cited 1×
“Previous studies have shown that the oncogenes RAS”
ResultPlowman, J., Dykes, D. J., Narayanan, V. L., Abbott, B. J., Saito, H., Hirata, T., & Grever, M. R. (1995) · PubMed · Cited by 25
Regulation of the Hypoxia-Inducible Factor-1α
Gassmann, M., Chilov, D., & Wenger, R. H. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46825-5_9 · Cited by 24
Bunnell, C. A., Supko, J. G., Eder, J. P., Clark, J. W., Lynch, T. J., Kufe, D. W., & Shulman, L. N. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100319 · Cited by 14
Research works printed but not linked: 1
- Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206–210 (1997). · DOI · Paper page
Cited by
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
“Multiple components of the HIF1 signalling pathway have been identified as candidate drug target”
BackgroundModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
“The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
BackgroundExploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
“Targeting HIF-1 The characteristics, functions and possibilities for targeting HIF-1 in cancer therapy have been recently reviewe”
BackgroundHypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
“HIF1 inhibitors with metabolic effects Investigators are also attempting to inhibit the HIF1 transcription factor in an effort to block the metabolic effects as well as other physiological pathways that are regulated by HIF1 in the solid tumour (such as angiogenesis”
BackgroundHypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
“HIF-1α is an oxygen-unstable protein that becomes stable in response to hypoxia, iron chelators, and divalent cations.(81,82) In cell culture under hypoxic conditions, HIF-1α mRNA levels did not change, but HIF-1α protein levels increased.”
Background
Metadata
- Authors
- Giaccia, A., Siim, B. G., & Johnson, R. S.
- Affiliations
- Stanford Medicine (US)
- University of Auckland (NZ)
- University of California San Diego (US)
- Corresponding author
- Johnson, Randall S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 803-811
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2075880922
- Cited by
- 631
- References
- 116
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 30 · 2019: 14 · 2018: 26 · 2017: 16 · 2016: 20 · 2015: 20 · 2014: 27 · 2013: 30 · 2012: 29
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, hypoxia-inducible factor, hypoxia, therapeutic target, oxygen sensing, transcriptional regulation, cancer, heart disease, stroke, therapeutic targeting
- MeSH terms
- Animals, Cardiovascular Diseases, DNA-Binding Proteins, Gene Expression Regulation, Humans, Neoplasms, Nuclear Proteins, Oxygen, Transcription Factors, Drug Design, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.